Heart failure with preserved ejection fraction in hamster

Unique model and predictive model of HFpEF related to a human like profile of metabolic comorbidities and non-alcoholic steatohepatitis (NASH)

Predictive model to test efficacy of compounds on diastolic dysfunction associated to liver complications

MODEL FEATURES

- Diet induced NASH Hamster – 20 weeks free choice diet
- Severe diastolic dysfunction
- Preserved systolic function
- NASH, fibrosis and metabolic syndrome

Reference compounds: PDE5 inhibitor, $PPAR_\gamma$ agonist

KEY PARAMETERS

- Cardiac function and geometry (Echography)
- Invasive left ventricle function (Millar probe)
- Exercise tolerance test (treadmill)
- Histology, gene / protein expression, biomarkers assays

Please contact us for tailor made protocol

PHARMACOLOGICAL VALIDATION WITH VARDENAFIL, A PDE-5 INHIBITOR

Echocardiography after 20 weeks of free choice diet (Vardenafil from week 15)

(Full data package upon request – Publication online: Briand & al, Metabolism 2021, PMID: 33444606)

➢ **Vardenafil alleviates NASH-induced diastolic dysfunction with preserved ejection fraction**



➢ **Vardenafil reduces plamsa level of NT proBNP and circulating lipids but has no effect on NASH**